[HTML] frontiersin.org

[HTML][HTML] Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver …

M Abdelrahim, A Esmail, J Xu, G Umoru… - Frontiers in …, 2022 - frontiersin.org
Background Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …
被引用次数：12 相关文章
[HTML] nih.gov

[HTML][HTML] Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver …

M Abdelrahim, A Esmail, J Xu, G Umoru… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver …

M Abdelrahim, A Esmail, J Xu… - Frontiers in …, 2022 - mdanderson.elsevierpure.com
Background: Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …

Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation.

M Abdelrahim, A Esmail, J Xu, G Umoru, A Saharia… - 2022 - ascopubs.org
e16202 Background: Cholangiocarcinoma (CCA) management is constantly being updated
in view of existing evidence in order to establish practice guidelines and consensus …

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver …

M Abdelrahim, A Esmail, J Xu, G Umoru… - Frontiers in …, 2022 - europepmc.org
Background Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver …

M Abdelrahim, A Esmail, J Xu, G Umoru… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …